8-K: Longevity Health Appoints New CEO, Secures Strategic Investment

Longevity Health Holdings, Inc. announced a strategic private placement and the appointment of Janakiram Ajjarapu as its new Chairman and Chief Executive Officer, signaling a shift towards an acquisition-focused growth strategy.

Summary

• Longevity Health Holdings, Inc. (the Company) entered into a Common Stock Purchase Agreement with International Capital Partners LLC (the Purchaser) on March 13, 2026.
• The Company sold 689,656 shares of common stock at $0.29 per share, totaling approximately $200,000, in a private placement.
• The proceeds from the offering are intended for working capital and other general corporate purposes.
• Janakiram Ajjarapu was appointed Chairman of the Board and Chief Executive Officer, effective March 16, 2026.
• Mr. Ajjarapu is the managing member of, and holds a direct minority interest in, the Purchaser, and serves as the trustee of a family trust holding the remaining membership interests in the Purchaser.
• Rajiv S. Shukla stepped down from his positions as CEO, Class III director, and Chairman of the Board, effective March 16, 2026, by mutual agreement related to the Company's strategic objectives.
• Mr. Shukla will receive monthly severance payments of $30,000 for a period of 12 months, which will be extended to 18 months if the Company consummates a transaction resulting in a change of control (50% or more voting power) within three months of the effective date of the Separation Agreement.
• Mr. Shukla is also entitled to a one-time lump sum cash payment of $480,000 for his accrued and unpaid bonus upon the closing of a future capital raise of at least $1 million.
• All vested and unvested stock options or other equity awards held by Mr. Shukla were forfeited upon the cessation of his employment.
• The Company is required to file a resale registration statement for the shares sold to the Purchaser within 60 calendar days of the closing date and use its best efforts to have it declared effective by the SEC as soon as practicable, but no later than the earlier of 30 calendar days after the filing deadline or 5 business days after SEC notification of no review.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as new capital and leadership with a clear acquisition strategy could revitalize the company, though the small capital raise and significant severance package introduce some caution.

Positives

• Secured approximately $200,000 in capital through a private placement, providing immediate working capital and funds for general corporate purposes.
• Appointment of Janakiram Ajjarapu as Chairman and CEO, who brings a stated focus on driving acquisition-focused growth and a strong track record in scaling businesses.
• Mr. Ajjarapu's strategic investment in the Company aligns his interests with those of existing stockholders, demonstrating commitment to long-term success.
• Outgoing CEO Rajiv Shukla will serve as an advisor during the leadership transition, ensuring continuity, and remains a significant shareholder in the Company.

Negatives

• The capital raise of $200,000 is a relatively small amount, especially when considering the $480,000 bonus payment to the outgoing CEO is contingent on a *future* capital raise of at least $1 million, suggesting the current raise is insufficient for broader strategic needs.
• A significant severance package for the outgoing CEO, including $30,000 per month for 12-18 months and a $480,000 bonus contingent on a future capital raise, represents a substantial financial obligation.
• The forfeiture of all vested and unvested equity awards for the outgoing CEO, while part of the separation agreement, could be viewed as a negative for executive incentives or a signal of past performance issues, though the filing states it was a mutual agreement.
• The Company is an 'emerging growth company' and has 'None' for securities registered pursuant to Section 12(b) of the Act, indicating it is not listed on a major national securities exchange (though it is listed on OTCQB).

Risks

• Ability to successfully execute its stated acquisition strategy.
• Obtaining sufficient additional capital to fund future acquisitions and ongoing operations.
• Managing potential dilution from future financing activities required for acquisitions or operations.
• Challenges in integrating acquired businesses and realizing expected synergies.
• Maintaining its listing status on the OTCQB market.
• Responding effectively to competitive pressures within the bio-aesthetics and healthy aging industry.
• General risks and uncertainties described in Longevity's Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission.

Future Outlook

The Company intends to use the proceeds from the current offering for working capital and other general corporate purposes. Under the new leadership of Janakiram Ajjarapu, Longevity Health Holdings plans to pursue disciplined, value-accretive acquisitions to expand its operations, grow profitability, and create long-term value for stockholders while maintaining a prudent capital structure.

Management Comments

• "Ram brings a strong track record of scaling businesses and executing value-creating transactions." Rajiv Shukla, outgoing Chairman and Chief Executive Officer.
• "We look forward to his leadership as Longevity seeks to advance its growth strategy through acquisitions as a public company." Rajiv Shukla.
• "I am excited to join Longevity and help build the Company's acquisition platform." Mr. Ajjarapu.
• "My investment and leadership commitment reflect my confidence in Longevity's potential." Mr. Ajjarapu.
• "We intend to pursue disciplined, value-accretive acquisitions that expand our operations, are accretive to earnings, grow profitability, and create long-term value for our stockholders while maintaining a prudent capital structure." Mr. Ajjarapu.

Industry Context

StockSavvy.ai notes that Longevity Health Holdings, a bio-aesthetics company, is pivoting to an acquisition-focused growth strategy under new leadership. This move could be a response to the highly competitive and rapidly evolving aesthetics and healthy aging market, where consolidation and strategic partnerships are common. The new CEO's background in diverse industries like IT and ethanol production, rather than directly in bio-aesthetics, suggests a focus on business management and deal-making capabilities to drive growth through M&A, potentially diversifying or expanding the company's product portfolio beyond its current cosmetic lines (Elevai Exosomes, Carmell Secretome).

Comparison to Industry Standards

• No specific comparable companies, projects, or results are mentioned in the filing to allow for a direct comparison to industry standards or global benchmarks. The filing focuses on internal corporate actions and future strategy rather than performance metrics against peers.

Management Changes

Corporate Governance

Related Party Transactions

• Janakiram Ajjarapu, the newly appointed CEO and Chairman, is the managing member of, and holds a direct minority membership interest in, International Capital Partners LLC, the Purchaser in the private placement. He also serves as the trustee of a family trust that holds the remaining outstanding membership interests in the Purchaser.

Stakeholder Impact

• **Shareholders**: Potential for long-term value creation if the new acquisition strategy is successfully executed, but also immediate dilution from the private placement. The new CEO's personal investment aligns his interests with shareholders.
• **Employees**: New leadership may bring changes in company direction, culture, and operational focus, potentially impacting roles and responsibilities.
• **Customers**: Future acquisitions could lead to an expanded product portfolio or enhanced services in the bio-aesthetics and healthy aging market.
• **Creditors**: The capital raise provides additional working capital, which could improve the Company's short-term liquidity and financial stability.

Next Steps

• The Company will use the proceeds from the offering for working capital and other general corporate purposes.
• The Company is required to file a resale registration statement for the 689,656 shares within 60 calendar days after March 16, 2026.
• The Company will use its best efforts to cause the resale registration statement to be declared effective by the SEC as soon as practicable, but no later than the earlier of 30 calendar days after the filing deadline and 5 business days after SEC notification of no review.
• New CEO, Mr. Ajjarapu, intends to pursue disciplined, value-accretive acquisitions to expand operations and grow profitability.
• Outgoing CEO, Mr. Shukla, will provide occasional assistance to the Company during his severance period, including making periodic introductions to his financial and commercial contacts.
• The Company will file an amendment to this Current Report on Form 8-K within four business days if any material plan, contract, or arrangement is entered into or any grant or award is made in connection with Mr. Ajjarapu's appointment as Chief Executive Officer.

Key Dates

Recommendation

The company is undergoing a significant leadership change and strategic pivot towards acquisitions, backed by a new, albeit small, capital infusion. While the new CEO's stated focus on value-accretive acquisitions and his personal investment are positive signals, the success of this strategy is uncertain and carries inherent risks, including the need for substantial future capital. The significant severance package for the outgoing CEO, contingent on a larger future capital raise, also warrants caution. Investors should hold to observe the execution of the new strategy and further financial developments before making a more definitive investment decision.

Keywords

Longevity Health Holdings, XAGE, private placement, CEO appointment, Chairman appointment, capital raise, acquisition strategy, corporate governance, bio-aesthetics, longevity, healthy aging, cosmetic products, SEC filing, 8-K